Aion Therapeutic Inc's (CSE:AION) Dr. Stephen Barnhill tells Proactive that the group's proprietary and patented combinatorial mushroom preparations, AION F7 and AION F8, showed high efficacy in killing multiple types of breast cancer cells. Dr Barnhill says the preparations demonstrated direct killing of HER2+ breast cancer cells, ER+/PR+ breast cancer cells, and triple-negative breast cancer cells by direct cytotoxicity, a similar effectiveness as trastuzumab, an FDA approved monoclonal antibody treatment for HER2+ breast cancer sold under the brand name Herceptin.
Aion Therapeutic says its medicinal mushroom highly effective at killing breast cancer cells
